Sanofi highlights progress of developmental products

Sanofi has hosted a presentation detailing the progress of its various pipeline projects, which include 65 new molecular entities.

As part of its efforts to transform its research and development capabilities, the company has made significant investments in new talent and has taken 17 molecules to the phase III development or regulatory submission stage.

In the last two months, the firm has received recommendations from Europe's Committee for
Medicinal Products for Human Use for the drugs Zaltrap and Lyxumia, with regulatory milestones also expected for drugs such as Aubagio, Lemtrada and Kynamro in the next six months.

Meanwhile, phase III trial data for therapies including eliglustat, otamixaban, iniparib and SAR302503 are also anticipated in the coming half-year.

Dr Elias Zerhouni, president for global research and development at Sanofi, said: "We feel we have the ingredients to ensure research and development contributes to Sanofi’s goal of sustainable growth in the coming years while rigorously managing costs."

This comes after the firm announced the appointment of Dr Gary Nabel as the new chairman of its strategic development and scientific advisory council earlier this month.